Taiko Pharmaceutical Co Ltd

Capital Structure and Liquidity Taiko Pharmaceutical maintains a strong liquidity position with JPY 4.26 billion in cash and equivalents, representing 34.8% of total assets. The company's price-to-book ratio of 1.72 and debt-to-equity ratio of 0.1 indicate a conservative capital structure with minimal leverage. A current ratio of 3.36 further supports its ability to meet short-term obligations. ### Profitability and Returns The company's return on equity (ROE) of 10.85% and return on assets (ROA) of 7.53% outperform the median ROE of 6.2% and ROA of 4.1% for Japanese pharmaceutical firms. Gross margin of 54.4% (JPY 3.48 billion gross profit on JPY 6.40 billion revenue) is in line with industry norms, but operating margin of 7.1% (JPY 452 million operating income) suggests moderate cost control. ### Segments and Geographic Exposure The Pharmaceutical Product segment dominates revenue, accounting for 78% of total sales based on disclosed segmental data. The company's geographic exposure is concentrated in Japan, with no material international revenue disclosed in recent filings. ### Growth Trajectory Analysts project 5.5% revenue growth to JPY 6.75 billion in the current fiscal year, based on mean estimates. This would represent a 5.6% increase from the JPY 6.397 billion reported in the latest period. The price-to-earnings ratio of 15.88 suggests the market is pricing in moderate earnings growth expectations. ### Risk Factors The company faces low liquidity risk with JPY 4.26 billion in cash and no immediate filing-based liquidity flags. Dilution risk is also low, with no near-term pressure from share issuance or convertible instruments. The conservative capital structure and strong cash position provide a buffer against potential revenue volatility in the pharmaceutical segment. ### Recent Events Recent 10-K filings show no material changes in business operations or regulatory status. The company continues to focus on its core gastrointestinal drug portfolio while expanding its infection control product line using chlorine dioxide gas technology.